February 6, 2019 / 4:35 PM / in 3 months

Sanofi blood disorder drug wins FDA approval

Feb 6 (Reuters) - The U.S. Food and Drug Administration (FDA) said on Wednesday it had approved Sanofi SA’s drug to treat a rare blood-clotting disorder in adults in combination with standard-of-care treatments.

The treatment, called Cablivi, is already approved in the European Union as a treatment for acquired forms of the disorder, called thrombotic thrombocytopenic purpura.

Cablivi should come with a warning about the risk of severe bleeding, the FDA said. (Reporting by Manogna Maddipatla in Bengaluru; Editing by Sai Sachin Ravikumar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below